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Bayesian econoMetRic Modelling of oBseRvational data foR  
cost-effectiveness analysis
Saramago Goncalves P1, Welton NJ2, Claxton K1, Soares M1
1University of York, Heslington, York, UK, 2University of Bristol, Bristol, UK
Objectives: In the absence of evidence from randomised controlled trials on the 
relative effectiveness of treatments, cost-effectiveness analyses (CEAs) may use 
observational evidence instead. Treatment assignment is not, however, randomised, 
and naïve estimates of treatment effect may therefore be biased. To appropriately 
deal with this form of bias, one may need to adjust for observed and unobserved 
confounders. In this work we explore these adjustment strategies within a case 
study of negative pressure wound therapy (NPWT) in the healing of surgical wounds 
healing by secondary intention (SWHSI). MethOds: Time to healing of SWHSI 
patients, the main effectiveness outcome, was estimated using i) OLS models, ii) 
OLS model adjusting for potential confounders and iii) two-stage instrumental vari-
able (IV) models. All econometric models were Bayesian and used MCMC simula-
tion. CEA estimates were obtained for selected models. Results: The case study 
was a longitudinal cohort study that included 393 participants followed up by on 
average 500 days. Unadjusted estimates of the additional days NPWT patients take 
to heal was 69.1 (mean, SE= 10.2), compared to other treatments. When adjusting 
for observables, 77.2 (mean, SE= 19.9) and when using the IV approach, 61.0 (mean, 
SE= 64.9) days were estimated. NPWT was not cost-effective across all approaches 
implemented. cOnclusiOns: This study demonstrates the feasibility of analysing 
observational evidence for CEA by adjusting for both observable and non-observable 
confounders. Within the case study, we could not demonstrate that the existing 
endogeneity affects the effectiveness of NPWT, and thus cost-effectiveness results 
were consistently negative.
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Objectives: NSCLC accounts for approximately 85% of lung cancers globally 
and is associated with poor prognosis and a substantial burden to patients, soci-
eties and economies. Two systematic literature reviews (SLRs) were conducted 
to explore NSCLC and the associated societal burden (indirect and direct costs; 
SLR1) and impacts on patient HRQoL (SLR2) across Europe. MethOds: Both SLRs 
were conducted using the OVID search engine and reviewed: Medline® in pro-
cess (PubMed) and Embase (OVID) for SLR 1 and 2, EconLit (EBSCOhost) and NHS 
Economic Evaluation Database for SLR1, and PsycINFO for SLR2. Searches were 
limited to human studies, English language and the past 10 years (July 2004 to July 
2014 [SLR1] and June 2014 [SLR2]). Additional pragmatic searches were conducted 
of oncology organisation websites and conference proceedings of the American 
Society of Clinical Oncology (ASCO) Annual Meetings (2009–2014). Results: Six 
publications on indirect costs (including lost productivity) and 18 on direct costs 
were identified through SLR1. Indirect costs were high in relation to total costs. 
Reporting of direct costs was diverse; in-patient stay, diagnostic/staging and treat-
ment costs including medication and surgery were identified as major cost driv-
ers. SLR2 identified 59 publications; HRQoL was reduced in patients with NSCLC 
when compared to the general population. Specific domains affected included 
emotional functioning (notably, depression and anxiety) and physical function-
ing. Generally, impacts were more unfavourable for patients with late-stage or 
progressive NSCLC and those receiving later lines of treatment. cOnclusiOns: 
Data suggest the societal burden of NSCLC is substantial; however heterogene-
ity in study designs, reporting and evaluation methods limit cost comparisons. 
While NSCLC differentially impacts domains of HRQoL, the impact on daily activi-
ties, work, cognitive function and social functioning was not commonly reported. 
Further research to explore particular HRQoL domains and quantify the societal 
burden of NSCLC is ongoing.
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Objectives: Estimates of expected lifetime survivals and lifetime costs for 
cohort with specific conditions are usually needed in cost-effectiveness analysis. 
However, the survival data of followed-up patients were often censored with high 
rates and observed expenditures were incomplete. It is desirable to develop reli-
able and robust methods for extrapolating survival and cost functions beyond the 
follow-up. MethOds: We propose using a semi-parametric extrapolation method 
to replace parametric survival models for estimating lifetime survival rates. We 
extrapolate the lifetime monthly mean costs using a weighted average of mean 
expenditures of patients in their final years and months prior to their final years. 
The weights are functions of hazards which can be estimated from the extrapolated 
lifetime survival rates. The expected lifetime cost can be estimated by summing the 
product of the estimated survival probabilities and monthly mean costs. Results: 
We evaluate performance of the proposed approach using simulated data and 
empirical data. For demonstration, we use population-based claims data from 
the Taiwan National Health Insurance to establish cohorts of ischemic stroke and 
intracerebral hemorrhage and estimate the lifetime direct medical costs of first-ever 
stroke patients. We found that life expectancy of patients diagnosed with intracer-
ebral hemorrhage and ischemic stroke is about the same of 9 years since the onset 
of stroke. The expected lifetime direct medical costs are also about the same amount 
of US$ 35,000 for both cohorts. cOnclusiOns: We demonstrated the proposed 
semi-parametric method of survival extrapolation performed well using simulated 
data and empirical data. We also showed in the simulation that even perfectly fitted 
parametric model may not be accurate for long-term extrapolation. Our estimates 
Objectives: Cervical cancer (CC) is one of the world’s deadliest forms of cancer. 
In Ukraine during the previous decade incidence rates for CC has been grad-
ually increasing, taking nowadays the 2nd place of cancers among women of 
reproductive age. The causative agents of CC are high-oncogenic-risk types of 
Human Papillomaviruses (HPVs). Central role in CC development prevention is 
taken by screening programs. Maximization of effectiveness of screening strate-
gies increases the significance of elaboration of the needed methods. From an 
economic point of view screening strategies are evaluated through cost-utility 
analysis. Different variations of cervical screening strategies are implemented 
all over the world, but their expected utilities for Ukrainian population are not 
assessed. MethOds: 1257 cervical smears from Ukrainian women aged 19 – 65 
were tested (HPV typing test and cytological testing). Obtained results of labora-
tory testing formed the basis for developing of simulation-optimization technique, 
based on Markov model. Screening strategies, with HPV test only, cytological test 
only or both tests depending on the differences in clinical and epidemiological 
history of the patient, were evaluated. Results: Simulation shows maximum of 
diagnostic utility for HPV test, as a single screening strategy, in women aged 29-30 
years. Screening with cytological test only increases its utility with the increase 
of patients’ age. Combined screening strategy based on both HPV and cytologi-
cal tests shows maximum of utility for HPV test when using it among younger 
women (< 21 years old) and for cytological test when using it with women aged 
> 21. Markov chain was designed for assessment of optimal screening intervals for 
each woman, depending on her previous medical history and age. cOnclusiOns: 
The study provides simulation-optimization techniques for development of cervi-
cal screening recommendations in Ukraine. According to the results of the mod-
eling, the optimal screening strategy depends on previous medical history and 
age individually.
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Objectives: The global prevalence of obesity is rising rapidly, highlighting the 
importance of understanding risk factors related to the condition. Childhood 
obesity, which has itself become increasingly prevalent in recent years, is an 
important predictor of adulthood obesity. Studies suggest that the protein con-
tent of milk consumed in infanthood is an important predictor of weight gain in 
childhood. For instance, there is evidence that a lower-protein formula for non-
exclusively breast-fed infants of overweight or obese mothers (SHAPE) can offer 
such advantages over standard infant formulas. The current study used predictive 
health economic modelling to determine the long-term clinical and economic 
outcomes associated with the SHAPE formula compared with a standard formula 
when used in Mexico. MethOds: A discrete event simulation was constructed to 
extrapolate the outcomes of trials on the use of formula in infanthood to changes 
in lifetime body mass index (BMI), the health outcomes due to the changes in BMI, 
and the healthcare system costs, productivity and quality of life impact associated 
with these outcomes. Results: The model predicts that individuals who receive 
SHAPE in infancy go on to have lower BMI levels throughout their lives, are less 
likely to be obese or develop obesity-related disease, live longer, incur fewer health 
system costs and have improved productivity. cOnclusiOns: Simulation-based 
economic modelling suggests that the benefits seen in the short term, with the 
use of SHAPE over standard formula, could translate into considerable health 
and economic benefits in the long term. Modelling over such long timeframes 
is inevitably subject to uncertainty. Further research should be undertaken to 
improve the certainty of the model.
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away fRoM univeRsal econoMic Models?
Gani R, Lauks S, Blogg K
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bAckgROund: Manufacturers developing new medicines must conduct numer-
ous reimbursement applications in multiple geographies before their treatments 
became widely used. This provides a challenge when developing economic models 
in meeting these varied demands. Planning an effective strategy requires a clear 
understanding of the variation in requirements from different reimbursement 
authorities. Objectives: The aim of this research was to review the submission 
guidelines from several leading HTA agencies to identify the similarities and dif-
ferences between them. In addition, we assessed options to develop a universal 
economic model and have it incorporated across these agencies. MethOds: 
Submission guidelines published by HTA authorities in UK, Germany, France, 
Sweden, Netherlands, Australia and Canada were reviewed. Initiatives from 
EUnetHTA and EMA were also included. Model structure and methodology were 
compared to assess variability and make recommendations on the acceptability and 
likelihood of having a single economic model suitable for these bodies. Results: 
Cost-utility analysis was found to be the preferred method of assessing cost-
effectiveness, with Germany being the most notable exception. Good practice for 
conducting literature reviews and indirect comparisons were broadly similar, with 
NICE providing the greatest detail. Mapping QoL was widely accepted, but there 
was a preference for PROs collected during RCTs using EQ-5D and disease-specific 
instruments. There is also a joint HTA-Regulatory advice pilot between multiple 
HTA agencies and the EMA underway, with 13 initial joint assessments having been 
completed as of March 2015. cOnclusiOns: Economic evaluation requirements are 
comparable across many HTA agencies, and should be closely followed to optimize 
economic models. Ongoing initiatives are allowing cross-border collaborations to 
become more commonplace. These activities mean manufacturers are now able 
to engage in new types of model design, both universal and flexible enough for 
local adaptation.
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between 1960 and 2015 in English language. Phase II, III or IV clinical trials with at-
least one study arm assessing a treatment of interest were included. PRO studies 
(not limited to RCTs) reporting quality-of-life (QoL) data for these compounds were 
included. Additionally, information was extracted from product package inserts 
of molecules within FDA indication. Archives of 27 HTA bodies were searched for 
qualifying HTAs of these compounds as well. Patient characteristics, primary and 
secondary endpoints, safety, QoL and reimbursement decisions were extracted 
exhaustively from qualifying studies and HTAs. Results: So far, data are avail-
able for 15 cancers, including 90 agents in 487 studies. The interactive, user-friendly 
MS-Excel® based tool can be used to study any selected cancer, including conduct 
meta-analyses, generate summaries and reports of clinical, PRO and HTA data. The 
registry provides functionality for a user to make desired assessments via multiple 
variables such as line of treatment, tumor-stage, molecule, grade of adverse events 
and so on. cOnclusiOns: OncoLitBank provides up-to-date data and a robust 
platform that can be easily used for systematic reviews, to conduct direct and indi-
rect comparisons through meta-analyses, to inform economic models, perform 
landscape analyses, produce value dossiers,and to create target product profiles and 
value development plans. Expansion of searches to other literature databases and 
trial registries and inclusion of economic and epidemiology studies are underway.
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Objectives: To generate costs and costing algorithms for treatment and supportive 
drugs in oncology using provincial (Ontario) administrative databases. MethOds: 
A cohort of women diagnosed with breast cancer (BC) (ICD-9 174.x) was identi-
fied from the Ontario Cancer Registry (2007-2010). Firstly, the Ontario Drug Benefit 
Formulary (ODBF), New Drug Funding Program (NDFP) and Activity Level Reporting 
(ALR) databases was used in which BC-specific treatments (chemotherapies and 
hormonal therapies) and supportive drugs were identified. Secondly, unit costs were 
applied to calculate the overall and per drug costs in each database. Lastly, costing 
algorithms were generated to conduct the costing analyses. Results: We identified 
30,338 women diagnosed with BC. All chemotherapies and hormonal therapies were 
named as well as anti-nausea, pain (opioid and non-opioid), anti-infectives, and 
blood products for supportive drugs. Outputs include number of patient cases with 
at least one treatment or supportive drug being utilized and total costs. Preliminary 
results for the 20,076 BC cases prescribed a drug in ODBF totalled $69.5 million in 
which $37.5 million was treatment-specific. cOnclusiOns: We have generated 
preliminary ODBF costs for oncology drugs in BC and costs for the NDFP and ALR 
databases will be determined next. These costing algorithms will allow for the calcu-
lation of oncology treatment and supportive drug costs in different cancer cohorts.
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Objectives: Repositories of “big data” have the potential to play a pivotal role in 
advancing Alzheimer’s disease (AD) research. Globally, AD-specific data are being 
generated and aggregated into research databases. An environmental scan was 
conducted to identify worldwide AD-specific databases and types of data being 
aggregated and used for AD research. MethOds: A Google search was conducted 
monthly starting in September 2014 to present. For each database, its URL, geo-
graphic location, funding source, and type of data collected and/or stored were 
identified. A categorization scheme was established to classify types of data. Three 
reviewers independently categorized the data as: 1 = claims, 2 = laboratory, 3 = 
genetic, 4 = imaging, 5 = patient/caregiver-reported questionnaires, 6a= longitudi-
nal study, 6b = patient registry, 7 = clinical data, 8 = electronic medical records, 9 = 
neuropathology, and O = other. A fourth reviewer resolved discrepancies. Results: 
A total of 53 AD databases were identified, both within (28/53) and outside the U.S. 
(21/53). Sources from outside the U.S. include United Kingdom, Australia, Belgium, 
France, etc. Four databases represent U.S. and non-U.S. collaborations. The National 
Institutes of Health is the most common funding source (14/53). Clinical data were 
found to be the most common (30/53); whereas, databases containing AD-specific 
claims data appear to be lacking. Additional gaps include a comprehensive database 
linking claims data with patient-level data from AD longitudinal studies, patient 
registries, electronic medical records, or genetic data. Patient registry databases 
lack pre-diagnosis and early-life data, as they enroll patients upon diagnosis with 
AD or mild cognitive impairment. cOnclusiOns: Various types of data are being 
aggregated into numerous AD-specific research databases worldwide. However, gaps 
exist that may limit the utility of these databases in making advances in the AD 
research. Efforts are needed to explore opportunities to merge and expand these 
databases to fill these critical gaps.
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wHicH ones aRe Patients talking aBout?
Bell HG1, Schifano L1, Rodriguez H2, Pierce C2, Dasgupta N2, Shaikh S3, Powell GE1
1GSK, RTP, NC, USA, 2Epidemico, Boston, MA, USA, 3GSK, Uxbridge, NC, USA
Objectives: Social Listening through digital media may offer a unique opportunity 
to enhance traditional pharmacovigilance strategies. The objective of this pilot study 
was to evaluate the breadth of pharmaceutical products and vaccines most com-
monly discussed on Facebook and Twitter and how these data may inform future 
research in this area. MethOds: Publically available Facebook and Twitter posts 
of lifetime direct medical costs for first-ever stroke patients can have implication 
in public health policy planning and clinical decision making.
ReseaRcH on MetHods – databases & Management Methods
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Objectives: Several indices have been developed to adjust for the effects of comor-
bid conditions in observational studies. This study aimed to determine which among 
selected indices provides the optimal covariate in cost analyses assessing resource 
utilisation between different treatment strategies using a UK primary care data-
base. MethOds: A retrospective analysis of UK patients continuously registered 
with a single general medical practice between 01/01/2007 and 01/01/2011 was con-
ducted using the Clinical Practice Research Datalink GOLD dataset (CPRD). Three 
comorbidity indices were compared: the Charlson Comorbidity Index, original ver-
sion (CCI) and 2008 adaptation (CCI-2008), and the Quality Outcomes Framework 
(QOF). In addition, we considered a bespoke index based on an unweighted count 
of diseases included in the Charlson indices. Two resource use outcomes were 
analysed: 1) the monthly frequency of primary care consultations; and 2) annual 
count of biological tests reported over the calendar year 2010. The sensitivity of 
the comorbidity indices were evaluated for three different look-back periods: 12, 
24 and 36 months. For each outcome, we fitted mixed linear regression models 
with comorbidity index, age and gender as fixed-effects factors and covariates, and 
general practice as random intercept. Comorbidity indices were ranked according to 
goodness-of-fit, assessed by R2 and Akaike’s Information Criterion (AIC). Results: 
4,694,610 patients were included in the analysis. The CCI-2008 ranked highest based 
on correlation with both consultations (R2= 0.11) and tests (R2= 0.16), followed by the 
CCI (R2= 0.09 and R2= 0.14 for consultations and tests respectively) and then the QOF 
measure (R2= 0.08 and R2= 0.11 respectively). Unweighted counts of comorbidities 
showed similar AIC and R2 as their weighted counterparts. The same ranking was 
observed over the three co-morbidity look-back periods. cOnclusiOns: The CCI-
2008 performed better than CCI and QOF to predict units of primary care resource 
utilisation observed in UK general practice. Further analyses will determine whether 
these findings are confirmed when predicting health resource use costs and if repro-
ducible in other health systems with alternative data collection methods such as 
claims databases.
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Objectives: Multiple sclerosis (MS) is a degenerative neurologic disease that seri-
ously affects patients’ quality of life. Fingolimod is a sphingosine-1-phosphate 
modulator that traps lymphocytes in lymph nodes with neuroprotective effects. 
Our objective was to review the available evidence regarding its efficacy in disease 
progressions, relapse rate and brain atrophy and link it to possible phamaeconomic 
effects. MethOds: A systematic review of literature was performed in MEDLINE 
and Scopus. We included primary studies comparing fingolimod to placebo or other 
drugs regarding its efficacy in disease progression, relapse rate and brain atrophy. 
Retrospective designs and studies focusing on specific populations were excluded. 
Data regarding the outcomes of interest were extracted and processed with Review 
Manager 5.3. Results were presented with forest plots, and heterogeneity analysis 
was performed. We performed a literature review to assess the possible effect of 
these clinical outcomes in terms of costs and quality adjusted life years (QALY) in 
the Colombian context. Results: From the 1,344 references originally identified, 
only 3 had useful information. Two were placebo-controlled and the other one used 
interferon ß1a (IFß1a) as control. Information was available for 1.25 mg and 0.5 mg 
fingolimod dosing. Statistically significant differences in favor of fingolimod were 
found in annualized relapse rate, brain volume change, percentage of relapse and 
disease progression-free patients compared to placebo or IFß1a. Results EDSS and 
MSFC scales change were favorable to fingolimod but not statistically significant. 
Using data from various sources, we estimated that Colombian patients treated 
with fingolimod for 5 years might avoid a loss of 0.145 QALY and $ 5,029 of direct 
and indirect costs. cOnclusiOns: Fingolimod is superior to placebo and IFß1a in 
disease progression, relapse rate and brain atrophy. More studies are warranted, 
especially comparing fingolimod to other drugs. The estimated pharmacoeconomic 
effects are promising but must be interpreted with caution.
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Objectives: We created OncoLitBank, to capture data from clinical trials, patient 
reported outcomes (PRO) studies,and Health Technology Assessments (HTAs) in 
oncology. The registry is aimed to provide efficient access, and comprehensive anal-
yses of data for the evolving landscape of chemotherapy agents. MethOds: A sys-
tematic literature search was conducted on PubMed for chemotherapy compounds 
by cancer indications that were either FDA-approved or National Comprehensive 
Cancer Network (NCCN) recommended. The search was limited to studies published 
